| CTRI Number |
CTRI/2024/11/077509 [Registered on: 29/11/2024] Trial Registered Prospectively |
| Last Modified On: |
21/11/2024 |
| Post Graduate Thesis |
Yes |
| Type of Trial |
Interventional |
|
Type of Study
|
Drug Unani Other (Specify) [Therapeutic] |
| Study Design |
Randomized, Parallel Group, Active Controlled Trial |
|
Public Title of Study
|
Evaluation of efficacy of Dawa e Dhayabitus in Diabetes mellitus type 2 |
|
Scientific Title of Study
|
A randomized, parallel group, open label, active controlled clinical study to evaluate safety and efficacy of Dawa-i-Dhayabitus in Dhayabitus Harr Qism Thani (Diabetes Mellitus Type 2) |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Saiyed Fatema Anjum |
| Designation |
PG Scholar |
| Affiliation |
National Research Institute of Unani Medicine for Skin Disorders Hyderabad |
| Address |
Department of Moalajat, National Research Institute Of Unani Medicine for Skin Disorder, AG colony Road, opp. ESI Hospital, Erragadda, Hyderabad
Hyderabad TELANGANA 500038 India |
| Phone |
7620282464 |
| Fax |
|
| Email |
sydfatema09@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Prof Mohammad Nasar |
| Designation |
Professor |
| Affiliation |
National Research Institute of Unani Medicine for Skin Disorders Hyderabad |
| Address |
Department of Moalajat, National Research Institute Of Unani Medicine for Skin Disorder, AG colony Road, opp. ESI Hospital, Erragadda, Hyderabad
Hyderabad TELANGANA 500038 India |
| Phone |
8328446962 |
| Fax |
|
| Email |
drnasar.nriumsd@gmail.com |
|
Details of Contact Person Public Query
|
| Name |
Dr Saiyed Fatema Anjum |
| Designation |
PG Scholar |
| Affiliation |
National Research Institute of Unani Medicine for Skin Disorders |
| Address |
Department of Moalajat, National Research Institute Of Unani Medicine for Skin Disorder, AG colony Road, opp. ESI Hospital, Erragadda, Hyderabad
Hyderabad TELANGANA 500038 India |
| Phone |
7620282464 |
| Fax |
|
| Email |
sydfatema09@gmail.com |
|
|
Source of Monetary or Material Support
|
| National Research Institute Of Unani Medicine for Skin Disorders, AG colony Road, Opp. ESI Hospital, Erragadda, Hyderabad 500038 |
|
|
Primary Sponsor
|
| Name |
National Research Institute Of Unani Medicine for Skin Disorders |
| Address |
National Research Institute Of Unani Medicine for Skin Disorders, AG colony Road, Opp. ESI Hospital, Erragadda, Hyderabad-500038 |
| Type of Sponsor |
Research institution and hospital |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Saiyed Fatema Anjum |
National Research Institute Of Unani Medicine for Skin Disorders |
Moalajat OPD No. 1, Dept. of Moalajat, OPD Block,National Research Institute of Unani Medicine for Skin Disorders. AGs Colony Road, Opp. ESI Hospital, Erragadda, Hyderabad- 500038 Hyderabad TELANGANA |
7620282464
sydfatema09@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Institutional Ethics Committee, NRIUMSD, Hyderabad |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: E119||Type 2 diabetes mellitus without complications, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
DawÄ’-i-DhayÄbÄ«á¹us |
Dose & Route of Administration: 2.5g Safūf (Powder) twice daily orally with water Duration of therapy:12 weeks |
| Comparator Agent |
Tablet Metformin |
Dose: 500mg twice daily orally after meals
Duration of therapy: 12 weeks |
|
|
Inclusion Criteria
|
| Age From |
30.00 Year(s) |
| Age To |
65.00 Year(s) |
| Gender |
Both |
| Details |
Fasting Blood Glucose (FBG) Levels between 126 and 150 mg/dLÂ Â
(after 8-12 hours of fasting)Â
orÂ
Post-Prandial Blood Glucose (PPBG) Level between 200 and 250 mg/dLÂ
(after 2 hours of ingestion of meal)Â
Glycated Haemoglobin (HbA1c) between 6.5% and 8%Â Â
Patients willing to sign the written informed consent  Â
with / withoutÂ
Presence of any of the following symptoms of DhayÄbÄ«á¹us ḤÄrr Qism ThÄnÄ« (Type 2 Diabetes Mellitus):  Â
Uá¹ash Mufriá¹ (Polydipsia)Â Â
Kathrat-i-Bawl (Polyuria)Â Â
Kathrat-i-Ishtiha (Polyphagia)Â Â
Bawl Layli (Nocturia)Â
Burning sensation in palms and solesÂ
Naqs al-Wazn (Weight Loss)Â Â
I’ya (Fatigue) Â
DÌ£u‘f-i-‘Ām (General Weakness)Â
|
|
| ExclusionCriteria |
|
|
Method of Generating Random Sequence
|
Permuted block randomization, fixed |
|
Method of Concealment
|
Sequentially numbered, sealed, opaque envelopes |
|
Blinding/Masking
|
Open Label |
|
Primary Outcome
|
| Outcome |
TimePoints |
| Change in Fasting Blood Glucose (FBG), Post Prandial Blood Glucose (PPBG), HbA1c from baseline to post treatment at 12 weeks |
At baseline, 2, 4, 6, 8, 10 and 12 weeks |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| Improvement in symptoms on VAS from baseline to post treatment at 12 weeks |
At baseline, 2, 4, 6, 8, 10 and 12 weeks |
|
|
Target Sample Size
|
Total Sample Size="60" Sample Size from India="60"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
Phase 2 |
|
Date of First Enrollment (India)
|
05/12/2024 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="1" Months="6" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Yet Recruiting |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
As per the WHO, diabetes mellitus is defined as a heterogeneous metabolic disorder characterized by common feature of chronic hyperglycemia with disturbance of carbohydrate, fat and protein metabolism. Diabetes Mellitus is a leading cause of morbidity and mortality world over. It is expected to continue as a major health problem owing to its serious complications, especially end stage renal disease, IHD, gangrene of the lower extremities, and blindness in the adults. The rise in prevalence is more for Type 2 DM than Type 1DM. Diabetes is a major health issue that has reached alarming levels. Today, more than half a billion people are living with diabetes worldwide. According to IDF Atlas in 2021, it is estimated that 537 million people have diabetes, and this number is projected to reach 643 million by 2030, and 783 million by 2045. In addition, 541 million people are estimated to have impaired glucose tolerance in 2021. Direct health expenditures due to diabetes are already close to one trillion USD and will exceed this figure by 2030. Despite of advances in the treatment of Diabetes Mellitus, it becomes the major epidemic among NCDs. Treatment for diabetes mellitus includes insulin therapy and oral antidiabetic drugs. Oral anti-diabetic drugs include sulphonylureas(glimepiride, gliclazides), biguanides (metformin), thiazolidinediones(pioglitazone), DPP-4 inhibitors (sitagliptin, vildagliptin), and SGLT2 inhibitors (dapagliflozin), but these drugs have certain adverse effects, such as abdominal discomfort, nausea, vomiting, diarrhea, weight gain.[3,4] Therefore, search of safe and effective drug for Diabetes Mellitus is the thrust area for research in medical fields. Unani system of medicine (USM) offers treatment for Diabetes Mellitus type 2. Many classical prescriptions comprising single herbo-mineral drugs and pharmacopoeial formulations have been recommended for the management of diabetes mellitus type 2, which are safe and cost effective, such as Qurá¹£-i-TabÄshÄ«r,Qurá¹£-i-Kafoor, Qurá¹£-i-DhayÄbÄ«á¹us, SafÅ«f DhayÄbÄ«á¹us, Qurá¹£-i-GulnÄr, KushtaBaidha Murgh. Some of these drugs mentioned in Unani classical literature have not been explored scientifically regarding their safety and efficacy. DawÄ’-i-DhayÄbÄ«á¹us is one of the compound formulations described by physicians in classical Unani literature for the management of DhayÄbÄ«á¹us ḤÄrr, but its safety and efficacy has not been evaluated on scientific parameters. Therefore, present clinical trial entitled “A Randomized, Parallel Group, Open Label, Active Controlled Clinical Study to evaluate the Safety and Efficacy of DawÄ’-i-DhayÄbÄ«á¹us in DhayÄbÄ«á¹us ḤÄrr Qism ThÄnÄ« (Diabetes Mellitus Type 2)†has been planned. |